Literature DB >> 4046324

Transmission electron microscopy of urinary sediment in human acute renal failure.

A K Mandal, A H Sklar, J B Hudson.   

Abstract

Urinary sediments from 31 patients with acute tubular necrosis (ATN) were studied using transmission electron microscopy (TEM). Variable quantities of renal tubule cells (RTCs), characterized by abundant cytoplasmic organelles, were a consistent finding in these sediments. TEM analyses of well-preserved RTCs permitted identification of their nephron segment(s) of origin. On the basis of the severity of ultrastructural changes observed, the sediments were divided into three types. Type I (N = 11) and II (N = 8) consisted of homogeneous populations of severely and mildly affected RTCs, respectively, while Type III (N = 12) sediments were composed of a heterogeneous population of variably affected cells. A correlation was found between the sediment type and the severity of the clinical illness. Of the 11 patients with Type I sediments, only two survived and they required chronic dialysis support. In contrast, seven of eight patients exhibiting Type II sediments survived, with only one requiring temporary dialysis therapy. Patients with Type III sediments had an intermediate course, with six of seven survivors regaining sufficient renal function to remain off dialysis over a 3-month period of observation. Our study suggests that TEM of urinary sediment can provide a useful non-invasive means of studying patients with ATN.

Entities:  

Mesh:

Year:  1985        PMID: 4046324     DOI: 10.1038/ki.1985.118

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  2 in total

Review 1.  Management of acute renal failure in the elderly. Treatment options.

Authors:  A K Mandal; M Baig; Z Koutoubi
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

2.  Treatment considerations in acute renal failure.

Authors:  A K Mandal; R K Visweswaran; N R Kaldas
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.